肺炎克雷伯菌疫苗的研制进展
Development of vaccines for prevention of Klebsiella pneumoniae

肺炎克雷伯菌是导致院内呼吸道感染最常见的细菌，在革兰阴性菌导致的菌血症、泌尿系统感染中位居第二位。肺炎克雷伯菌菌株常发生耐药，使患者住院时间延长，对重症监护患者的影响尤其严重。为了减少肺炎克雷伯菌感染，临床上采取了很多预防性措施。针对肺炎克雷伯菌的免疫治疗包括主动免疫和被动免疫。其中，主动免疫的疫苗包括灭活疫苗、多糖疫苗、多糖结合疫苗、蛋白疫苗、纳米疫苗等新型疫苗。文章就肺炎克雷伯菌疫苗的研制进展作一综述。
：Klebsiella pneumoniae is the most common caof nosocomial respiratory tract, and the second most frequent caof Gram-negative bacteraemia and urinary tract infections. Drug resistant isolates remain an important hospital-acquired bacterial pathogen, prolong hospital stays, and are especially problematic in high impact medical areas such as intensive care units. A variety of preventive measures were applied to reduce such incidences.The immune therapies for Klebsiella pneumoniae include active immunization and passive immunization. Many trials for constructing effective vaccines are followed, including inactivated vaccines, polysaccharide vaccine, conjugate vaccine, protein vaccine, and nano vaccine. This review was about the development of vaccines for the prevention of Klebsiella pneumoniae